Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rand Ahmad, Samaneh Alaei & Hamid Omidian. (2018) Safety and performance of current abuse-deterrent formulations. Expert Opinion on Drug Metabolism & Toxicology 14:12, pages 1255-1271.
Read now
Read now
Joseph V. Pergolizzi$suffix/text()$suffix/text(), Flaminia Coluzzi & Robert Taylor$suffix/text()$suffix/text(). (2018) Transdermal buprenorphine for moderate chronic noncancer pain syndromes. Expert Review of Neurotherapeutics 18:5, pages 359-369.
Read now
Read now
Mohammad Hadi Foroughi, Maryam Akhgari, Farzaneh Jokar & Zahra Mousavi. (2017) Identification of undeclared active pharmaceutical ingredients in counterfeit herbal medicines used as opioid substitution therapy. Australian Journal of Forensic Sciences 49:6, pages 720-729.
Read now
Read now
David J. Mastropietro, Srinath Muppalaneni & Hossein Omidian. (2016) Deterred drug abuse using superabsorbent polymers. Expert Opinion on Drug Delivery 13:11, pages 1523-1531.
Read now
Read now
Maciej Gasior, Mary Bond & Richard Malamut. (2016) Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgraduate Medicine 128:1, pages 85-96.
Read now
Read now
Articles from other publishers (30)
Haiou Qu, William C. Smith, Xin Feng, Jiang Wang, Julia Pinto, Xiaoming Xu & Patrick J. Faustino. (2023) Asymmetrical Flow Field Flow Fractionation for Molar Mass Characterization of Polyethylene Oxide in Abuse-Deterrent Formulations. Journal of Chromatography A 1705, pages 464186.
Crossref
Crossref
Jeong Sun Sohn & Jin-Seok Choi. (2023) Design of Abuse-Deterrent Formulations Using Various Types of Thermal Deformed Starch (TDS). Journal of Pharmaceutical Innovation.
Crossref
Crossref
Aljoscha JanssenXuan Zhang. (2023) Retail Pharmacies and Drug Diversion during the Opioid Epidemic. American Economic Review 113:1, pages 1-33.
Crossref
Crossref
Golam Kibria, Bandaranayake Bandaranayake, Jiwen Zheng, Sau Lee & Celia Cruz. (2023) Stability of Abuse-deterrent properties of PEO-based Abuse-deterrent formulation. International Journal of Pharmaceutics 631, pages 122430.
Crossref
Crossref
Dhwani Rana, Sagar Salave & Derajram Benival. (2022) Emerging Trends in Abuse-Deterrent Formulations: Technological Insights
and Regulatory Considerations. Current Drug Delivery 19:8, pages 846-859.
Crossref
Crossref
Leyla Rezaei, Saikishore Meruva & Maureen D. Donovan. (2021) Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets. AAPS PharmSciTech 23:1.
Crossref
Crossref
Jeong Sun Sohn & Jin-Seok Choi. (2021) Development and evaluation of pseudoephedrine hydrochloride abuse-deterrent formulations using thermal modified rice starch. International Journal of Biological Macromolecules 182, pages 1248-1258.
Crossref
Crossref
Kanishka Rajput & Nalini Vadivelu. (2021) Acute Pain Management of Chronic Pain Patients in Ambulatory Surgery Centers. Current Pain and Headache Reports 25:1.
Crossref
Crossref
Siddhant Palekar, Pavan Kumar Nukala, Richa Vartak & Ketan Patel. (2020) Abuse deterrent immediate release film technology (ADRIFT): A novel bilayer film technology for limiting intentional drug abuse. International Journal of Pharmaceutics 590, pages 119944.
Crossref
Crossref
Saikishore Meruva, Leyla Rezaei, Prajwal Thool & Maureen D. Donovan. (2020) Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets. AAPS PharmSciTech 21:7.
Crossref
Crossref
C. Austin Zamarripa, Jennifer E. Naylor, Sally L. Huskinson, E. Andrew Townsend, Thomas E. Prisinzano & Kevin B. Freeman. (2020) Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. Psychopharmacology 237:5, pages 1471-1480.
Crossref
Crossref
Jun Jie Ong, Atheer Awad, Annalisa Martorana, Simon Gaisford, Edmont Stoyanov, Abdul W. Basit & Alvaro Goyanes. (2020) 3D printed opioid medicines with alcohol-resistant and abuse-deterrent properties. International Journal of Pharmaceutics 579, pages 119169.
Crossref
Crossref
Xin Feng, Ahmed Zidan, Nahid S. Kamal, Xiaoming Xu, Dajun Sun, Ross Walenga, Heather Boyce, Celia N. Cruz & Muhammad Ashraf. (2020) Assessing Drug Release from Manipulated Abuse Deterrent
Formulations. AAPS PharmSciTech 21:2.
Crossref
Crossref
Saikishore Meruva & Maureen D. Donovan. (2019) Polyethylene Oxide (PEO) Molecular Weight Effects on Abuse-Deterrent Properties of Matrix Tablets. AAPS PharmSciTech 21:1.
Crossref
Crossref
Saikishore Meruva & Maureen D. Donovan. (2019) Effects of Drug-Polymer Interactions on Tablet Properties During
the Development of Abuse-Deterrent Dosage Forms. AAPS PharmSciTech 20:3.
Crossref
Crossref
Nora VolkowHelene BenvenisteA. Thomas McLellan. (2018) Use and Misuse of Opioids in Chronic Pain. Annual Review of Medicine 69:1, pages 451-465.
Crossref
Crossref
Britni L. Lookabaugh & Charles F. Von Gunten. 2018. Essentials of Pain Medicine. Essentials of Pain Medicine
299
308.e1
.
J. Rick Turner. (2017) Commissioner Gottlieb and the Crusade Against Opioid Abuse: Baptism by Fire. Therapeutic Innovation & Regulatory Science 51:4, pages 400-403.
Crossref
Crossref
Nalini Vadivelu, Daniel Chang, Leandro Lumermann, Thomas Suchy, Matthew M. Burg & Manuel L. Fontes. (2017) Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting. Current Pain and Headache Reports 21:2.
Crossref
Crossref
J. David Haddox & Richard O. Mannion. (2016) A tale of 2 ADFs—with 2 different abuse-deterrent formulations. Pain 157:12, pages 2875-2875.
Crossref
Crossref
Yvette N. Lamb, Karly P. Garnock-Jones & Susan J. Keam. (2016) Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain. Drugs 76:18, pages 1759-1769.
Crossref
Crossref
Martin E Hale, Derek Moe, Mary Bond, Maciej Gasior & Richard Malamut. (2016) Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Management 6:5, pages 497-508.
Crossref
Crossref
PM Coplan, HD Chilcoat, SF Butler, EM Sellers, A Kadakia, V Harikrishnan, JD Haddox & RC Dart. (2016) The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics 100:3, pages 275-286.
Crossref
Crossref
Carmen Walter, Claudia Knothe & Jörn Lötsch. (2015) Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics 55:7, pages 751-767.
Crossref
Crossref
Theodore J. Cicero, Matthew S. Ellis & Zachary A. Kasper. (2016) A tale of 2 ADFs. Pain 157:6, pages 1232-1238.
Crossref
Crossref
Nora D. Volkow & A. Thomas McLellan. (2016) Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies. New England Journal of Medicine 374:13, pages 1253-1263.
Crossref
Crossref
Xiaoming Xu, Abhay Gupta, Manar Al-Ghabeish, Silvia N. Calderon & Mansoor A. Khan. (2016) Risk based in vitro performance assessment of extended release abuse deterrent formulations. International Journal of Pharmaceutics 500:1-2, pages 255-267.
Crossref
Crossref
Nathaniel Katz, Ernest A. Kopecky, Melinda O'Connor, Robert H. Brown & Alison B. Fleming. (2015) A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain 156:12, pages 2458-2467.
Crossref
Crossref
Kaoru Toyama, Naoki Uchida, Hitoshi Ishizuka, Takehiko Sambe & Shinichi Kobayashi. (2015) Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist. The Journal of Clinical Pharmacology 55:9, pages 975-984.
Crossref
Crossref
Aljoscha Janssen & Xuan Zhang. (2020) Retail Pharmacies and Drug Diversion during the Opioid Epidemic. SSRN Electronic Journal.
Crossref
Crossref